Plasma amyloid beta X‐42/X‐40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease
Open Access
- 28 June 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (8) , 5132-5142
Abstract
INTRODUCTION: Blood‐based biomarkers are a cost‐effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation‐immunoassay (IP‐IA) as a test for predicting cognitive decline.METHODS: We measured levels of amyloid beta (Aβ)X‐40 and AβX‐42 in immunoprecipitated eluates from the DELCODE cohort. Receiver‐operating characteristic (ROC) curves, regression analyses, and Cox proportional hazard regression models were constructed to predict AP by Aβ42/40 classification in cerebrospinal fluid (CSF) and conversion to mild cognitive impairment (MCI) or dementia.RESULTS: We detected a significant correlation between AßX‐42/X‐40 in plasma and CSF (r = 0.473). Mixed‐modeling analysis revealed a substantial prediction of AßX‐42/X‐40 with an area under the curve (AUC) of 0.81 for AP (sensitivity: 0.79, specificity: 0.74, positive predictive value [PPV]: 0.71, negative predictive value [NPV]: 0.81). In addition, lower AβX‐42/X‐40 ratios were associated with negative PACC5 slopes, suggesting cognitive decline.DISCUSSION: Our results suggest that assessing the plasma AβX‐42/X‐40 ratio via our semiautomated IP‐IA is a promising biomarker when examining patients with early or preclinical AD.Highlights: New plasma Aβ42/Aβ40 measurement using immunoprecipitation–immunoassay Plasma Aβ42/Aβ40 associated with longitudinal cognitive decline Promising biomarker to detect subjective cognitive decline at‐risk for brain amyloid positivityKeywords
This publication has 27 references indexed in Scilit:
- Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma BiomarkersJAMA Neurology, 2023
- Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
- An accurate fully automated panel of plasma biomarkers for Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centersAlzheimer's & Dementia, 2022
- Association of plasma Aβ40/Aβ42 ratio and brain Aβ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's diseaseNeurobiology of Aging, 2021
- Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tauAlzheimer's & Dementia, 2021
- Sensitivity of a Preclinical Alzheimer’s Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer’s diseaseJournal of Clinical and Experimental Neuropsychology, 2019
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011